X4 Pharmaceuticals Inc. (XFOR)
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
There are no comments here yet...